As described in Table 1, Table 2, Table 3 and Table 4, the nephroprotective effect of SGLT2 inhibitors, in the absence of diabetes, can be clearly appreciated in a number of renal diseases that are apparently independent of each other. This evidence concerns the gene SLC5A2 and kidney disorder.